Source: Annual Congress 2008 - Physiological response to exercise performance
Disease area: Airway diseases

Abstract

Background :
To examine whether procaterol, a short-acting bronchodilator, improves exercise performance in subjects with chronic obstructive pulmonary disease (COPD).
Methods:
Randomized, double blind, placebo-controlled, crossover trial In 10 COPD subjects aged 72.2 ± 4.2 (mean±SD) yrs, FEV₁ 43.4 ± 15 .8%pred
Methods:
All subjects completed the endurance shuttle walking test (ESWT) and spirometry at entry to the study. Spirometry was measured at three time and the best data was adopted., immediately after inhaled procaterol and repeated after 20 minutes, Subjects were divided into two groups: experimental group (group I) received procaterol 20 minutes before the ESWT, and the control group (group II) received a placebo 20 minutes prior to the ESWT. Following a washout time of a mean of 24 hours, the groups crossed over such that group I received placebo and group II inhaled procaterol.
Results:
Walking distance was significantly improved following procaterol when compared to placebo Table 1, p<0.05, however, there was no statistically significant between right after inhaled procaterol and twenty minute later.

Table1. Walking Distance of ESWT by SABA and Placebo

		SABA	Placebo
Walking distance (m)		457 (275.1)*	382(260.5)*
SpO2 (%)	Baceline	96.6(1.07)	4.8(2.39)
	End-exercise	85.1(7.75)	85.8(7.04)
HR(bpm)	Baceline	86.6(13.2)	84.8(9.3)
	End-exercise	115.7(19.0)	108.7(15.8)
Borg-Scale at end	Dyspnea	6.2(1.99)	5.8(2.62)
	Fatigue L/E	4.8(2.39)	4.7(2.0)

Mean(SD) *p<0.05

Conclusions:
Procaterol provided a sustained improvement in exercise performance for four hours in subjects with moderate to severe COPD.

Rating:

Share or cite this content

Citations should be made in the following way:
S. Hideaki, K. Chika, K. Ryou (Nagasaki, Japan). Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial. Eur Respir J 2008; 32: Suppl. 52, 3303

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 The effect of bronchodilators in the exercise capacity and thoracoabdominal mechanics of subjects with bronchiectasis: a randomized crossover, double-blinded, placebo-controlled trial Source: Virtual Congress 2020 – Exercise tolerance and functional status across respiratory diseases Year: 2020 A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009 A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001 A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009 A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006 Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021 Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers: a randomised, placebo controlled, cross-over study Source: Eur Respir J 2003; 22: Suppl. 45, 49s Year: 2003 A multicentre, double-blind, double-dummy, randomized, parallel group study to assess efficacy and safety of beclomethasone dipropionate and ease of handling of a breath operated aerosol inhaler in adults with reversible airways obstruction Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001 Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial. Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Effect of oral beta-alanine supplementation on muscle carnosine in patients with COPD: A double blind, placebo-controlled, randomized trial Source: Virtual Congress 2020 – Muscle, exercise capacity and symptoms of chronic lung disease: a physio update Year: 2020 A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 A randomized placebo controlled trial of AZD8999 (LAS190792) a novel dual acting bronchodilator in asthmatics Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017 A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008 A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics. Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010